Clinical Trial Failure Risk: The company's lead product candidates, particularly azenosertib, are in various stages of clinical development, and there is no guarantee that they will demonstrate sufficient safety and efficacy to obtain regulatory approval or achieve commercial success. Negative results in ongoing or future trials could significantly devalue the company.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, there is no assurance that Zentalis will obtain the necessary regulatory approvals from agencies like the FDA or EMA. The approval process is lengthy, expensive, and subject to unpredictable outcomes, potentially leading to delays or outright rejections.

Intense Competition Risk: Zentalis operates in the highly competitive oncology market. Many established pharmaceutical and biotechnology companies are developing or have already commercialized treatments for similar indications, posing significant challenges to market share, pricing, and product differentiation.